N/A N=144 Comparative Effectiveness of Dementia Care Strategies in Underserved Communities
Dementia
Primary: Change in Caregiver Burden at 6 and 12 Months — 29.99; 30.09; 28.1; 28.13 units on a scale — p=0.76
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=103 Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 84.0; 70.4; 91.7; 88.9 percentage of participants
N/A N=515 Use of Platelet-Rich Plasma (PRP) and Platelet-Poor Plasma (PPP) to Prevent Infection and Delayed Wound Healing
Elective Foot and Ankle Surgery.
Primary: Postoperative Infection and Delayed Wound Healing. — 2; 1; 17; 17 participants
Phase 2 N=26 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer
Recurrent Uterine Sarcoma · Uterine Carcinosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 4.3 percentage of participants
Phase 2 N=20 Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients
Melanoma
Primary: Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation of Study Drug, Related AEs, Immune-related AEs (IrAEs)…
N/A N=95 Treatment of Extraesophageal Reflux With the Reza Band UES Assist Device
Laryngopharyngeal Reflux
Primary: Percent Change in the Reflux Symptom Index (RSI) at 4 Weeks — -54.3 Per Cent Change — p=<0.05
Phase 4 N=203 A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Schizophrenia · Schizoaffective Disorder · Bipolar Disorder
Primary: Rate of 7-day Point Prevalence Abstinence at the End of the Relapse Prevention Phase (Study Week 53) in the Extended Duration Pharmacotherapy Group vs. the Placebo Group…
Phase 3 N=1,404 A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
Arthritis, Rheumatoid
Primary: Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib vs. Placebo) — -1.39; -1.37; -1.10 Scores on a scale — p=0.004
Phase 4 N=394 Study of Safety and Efficacy of 6 mL Synvisc-One (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial and Repeat Treatment
Osteoarthritis
Primary: Change From Baseline in WOMAC A1 Subscore at Week 26 — -28.0 units on a scale — p=<0.0001
N/A N=20 Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
Alzheimer's Disease
Primary: Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change — 2.5; 2.43 units on a scale
Phase 2 N=48 Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Male Breast Carcinoma · Recurrent Breast Carcinoma · Stage IV Breast Cancer AJCC v6 and v7
Primary: Recommended Dose Level for Phase II Testing (RPTD) (Phase I) — 2; 1; 1; 0 DLTs
N/A N=84 Bilateral Paravertebral Blockade (T7-10) vs. Incisional Local Anesthetic Administration for Pediatric Patients
Pain, Postoperative
Primary: Opioids Consumption Via PCA — 107.29; 100.17 ng/kg/min
Phase 1 N=22 Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects
Drug-induced Surface ECG Changes
Primary: Placebo, and Baseline-adjusted Changes in PR, QRS, J-Tpeak, Tpeak-Tend and QTc — 6.5; 2.3; 32.1; 5.1 ms — p=<0.05
Phase 4 N=403 Comparison of Insulin Mix25 Versus Mix50
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 — -1.52; -1.69 percentage of glycosylated hemoglobin
N/A N=98 A Web-Based Physical Activity Intervention in Adolescent Survivors of Childhood Cancer
Cancer
Primary: Differences in Change in Daily Average of Moderate and Vigorous Physical Activity (MVPA) Levels Between Groups — -2.58; -2.12; -7.78 minutes — p=0.90